awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q43492386-889CE3DE-824B-4AA5-B2E4-FBC016FD9EF2
Q43492386-889CE3DE-824B-4AA5-B2E4-FBC016FD9EF2
BestRank
Statement
http://www.wikidata.org/entity/statement/Q43492386-889CE3DE-824B-4AA5-B2E4-FBC016FD9EF2
De novo AML patients with favourable-intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened "GO question".
P2860
Q43492386-889CE3DE-824B-4AA5-B2E4-FBC016FD9EF2
BestRank
Statement
http://www.wikidata.org/entity/statement/Q43492386-889CE3DE-824B-4AA5-B2E4-FBC016FD9EF2
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
193c5fc80baf802731ef601af9bf82a55c2b3793
P2860
Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.